Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma

Clinical trial NCT01183949 · COMPLETED

Trial details

NCT number: NCT01183949
Sponsor: Astex Pharmaceuticals, Inc.
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Multiple Myeloma

Start date: 2010-11-01
Primary completion: 2014-12-01
Enrollment: 18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.